No signs of neurotoxicity were seen for 28 days after the first patient in a Phase 1 clinical trial was…
Articles by Steve Bryson PhD
Kyverna Therapeutics will use Verily Life Sciences’ high-resolution Immune Profiler to identify biomarkers to measure responses to KYV-101,…
Racial discrimination was found to be associated with increased inflammation among Black women with systemic lupus erythematosus (SLE) in…
A Phase 2b clinical trial of ESK-001, an oral treatment for systemic lupus erythematosus (SLE), has begun dosing patients,…
The Lupus Foundation of America (LFA) has launched a new awareness campaign to help Black/African American and Hispanic/Latina women…
A Phase 2 trial evaluating the safety and efficacy of daxdilimab, a potentially first-in-class treatment for people with active, proliferative…
Severe flare-ups of systemic lupus erythematosus (SLE) among patients were associated with a markedly higher risk of stroke, according…
Over 18 months, the approved therapy Lupkynis (voclosporin) lessened inflammation and prevented further kidney damage in systemic lupus…
The activity of a class of immune signaling proteins known as type I interferons — called IFN-1 — was markedly…
The first patient has been enrolled in RECAST DLE, a Phase 2 study evaluating daxdilimab, a potentially first-in-class therapy for…